Xconomy’s Digital Events →
Sarah Karlin-Smith covers regulation of the pharmaceutical industry for the Pink Sheet.
It will be difficult to compare Moderna, Inc. and Pfizer Inc.’s coronavirus vaccines based on their Phase 3 study designs, some vaccines experts said.
“Both trials appeared to be well designed,”... Read more »
Fast enrollment of the right patient populations will be critical to quickly conducting Phase III trials of COVID-19 vaccines and this will likely mean taking concerted steps to reach out to... Read more »
The US Health and Human Services agency isn’t ready to go all in on “pull” incentives to encourage the development of new antibiotics, the agency indicated in response to a new... Read more »
From Our Editors · Special Report
Becoming the Cell & Gene Therapy Hub
Sponsored · Whitepaper
Acknowledging various stakeholder networks and regulatory environment variances is essential to uncover the right decision-makers in support of biologics or biosimilars
Xconomy Insight · Special Report
Industry experts explain what it takes to launch a new biotech company
© 2007-2022, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.